Brussels, 11 December 2025 – The Association of the European Self‑Care Industry (AESGP) welcomes the political agreement reached between the Council and the European Parliament on the revision of the EU’s general pharmaceutical legislation. This landmark development marks a decisive step towards a modernised framework that ensures timely access to safe, effective, and affordable medicines for all Europeans.
Throughout the negotiations, AESGP has consistently championed a proportionate, fit-for-purpose regulatory approach that acknowledges the distinctive role of non-prescription medicines and empowers individuals to manage their health responsibly. Self-care is a cornerstone of resilient healthcare systems, and we are encouraged to see provisions aimed at streamlining regulatory processes, strengthening the internal market, and enhancing Europe’s pharmaceutical competitiveness.
The revision should build on the lessons learned from the impact assessment by addressing areas for improvement, while preserving what already works well. Maintaining proven elements of the current system is essential to safeguard the competitiveness of the European Union in global markets, while ensuring public health, patient empowerment, and respecting environmental considerations.
As the legislative package moves towards formal adoption and implementation, AESGP remains committed to constructive collaboration with EU institutions and stakeholders to ensure the framework delivers on its objectives. Promoting responsible self-care and safeguarding the availability of non-prescription medicines are essential to building sustainable healthcare systems and guaranteeing equitable access for all.